CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.


Participation Guidelines

Ages: 50 - 85 years

Gender: Both


Hoffman-La Roche

Start Date: 08/18/2016

End Date: 08/31/2020

Last Updated: 02/22/2018

Study HIC#: 1601017095

Get Involved

For more information about this study, contact:
Chenee Gallaher
+1 203-764-8100
chenee.gallaher@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Christopher H Van Dyck

Principal Investigator

Sub-Investigators